Chugai Pharmabody is a subsidiary of Chugai Pharmaceutical, a member of the Roche group, dedicated to creating innovative drugs for the benefit of patients. With a mission to solve unmet medical needs, Chugai Pharmabody Research (CPR) pioneers new frontiers in drug discovery. Leveraging their world-leading proprietary antibody engineering and cyclic peptide technology, they focus on developing innovative drugs that deliver better clinical outcomes.

Their cutting-edge technologies allow them to expand druggable targets and invent unique therapeutic actions, addressing clinical needs that have yet to be met. CPR has established themselves as a global leader in antibody and cyclic peptide drug discovery research by positioning themselves as a unified team and utilizing Singapore's strong infrastructure, highly-trained scientists, and supportive government policies. With patient well-being as their highest priority, CPR aims to create innovative drugs against diseases with high unmet medical needs worldwide.

They strive to become a top innovator in patient-centric healthcare by combining their strengths in science and technology with a diverse team of inclusive individuals